Nadja West Sells 809 Shares of Tempus AI, Inc. (NASDAQ:TEM) Stock

Tempus AI, Inc. (NASDAQ:TEM - Get Free Report) Director Nadja West sold 809 shares of the stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $51.11, for a total transaction of $41,347.99. Following the transaction, the director now directly owns 37,705 shares in the company, valued at $1,927,102.55. The trade was a 2.10 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Tempus AI Trading Up 0.5 %

TEM stock traded up $0.24 during midday trading on Friday, hitting $49.10. The company's stock had a trading volume of 9,329,504 shares, compared to its average volume of 4,780,820. The company has a quick ratio of 2.55, a current ratio of 2.69 and a debt-to-equity ratio of 8.17. Tempus AI, Inc. has a twelve month low of $22.89 and a twelve month high of $91.45. The company's fifty day moving average price is $54.02 and its 200 day moving average price is $52.54.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the stock. Piper Sandler decreased their price target on shares of Tempus AI from $70.00 to $55.00 and set a "neutral" rating for the company in a report on Tuesday. Needham & Company LLC upped their price target on shares of Tempus AI from $56.00 to $70.00 and gave the company a "buy" rating in a report on Tuesday, February 25th. Stifel Nicolaus cut shares of Tempus AI from a "buy" rating to a "hold" rating and upped their price target for the company from $45.00 to $65.00 in a report on Monday, November 11th. JPMorgan Chase & Co. cut shares of Tempus AI from an "overweight" rating to a "neutral" rating and upped their price target for the company from $50.00 to $55.00 in a report on Tuesday, February 25th. Finally, TD Cowen reiterated a "buy" rating and issued a $74.00 target price (up previously from $58.00) on shares of Tempus AI in a research note on Wednesday, February 5th. Six equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $61.18.

Remove Ads

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the company. ARK Investment Management LLC boosted its holdings in Tempus AI by 132.1% in the 4th quarter. ARK Investment Management LLC now owns 5,519,644 shares of the company's stock valued at $186,343,000 after purchasing an additional 3,141,487 shares during the period. Sumitomo Mitsui Trust Group Inc. boosted its holdings in Tempus AI by 166.0% in the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 3,239,093 shares of the company's stock valued at $109,352,000 after purchasing an additional 2,021,394 shares during the period. Nikko Asset Management Americas Inc. boosted its holdings in Tempus AI by 166.0% in the 4th quarter. Nikko Asset Management Americas Inc. now owns 3,239,093 shares of the company's stock valued at $109,352,000 after purchasing an additional 2,021,394 shares during the period. Franklin Resources Inc. boosted its holdings in Tempus AI by 240.5% in the 4th quarter. Franklin Resources Inc. now owns 2,762,173 shares of the company's stock valued at $93,251,000 after purchasing an additional 1,950,862 shares during the period. Finally, JPMorgan Chase & Co. boosted its holdings in Tempus AI by 86,947.2% in the 4th quarter. JPMorgan Chase & Co. now owns 1,653,896 shares of the company's stock valued at $55,836,000 after purchasing an additional 1,651,996 shares during the period. 24.22% of the stock is currently owned by institutional investors and hedge funds.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.